Takeda Pharmaceutical Company (4502) Q3 2025 earnings summary

Executive summary

• Year-to-date revenue grew 4.5% at constant exchange rates to JPY 3,528.2 billion, driven by growth and launch products up 14.6% at CER, now representing 47% of revenue.

• Core operating profit margin improved to 28.5%, up 1.6 percentage points year-over-year, reflecting efficiency gains and OPEX savings.

• Net profit rose 43.5% year-over-year to JPY 211.1 billion, with core net profit up 8.6% to JPY 698.9 billion.

• CEO Christophe Weber announced retirement in June 2026, with Julie Kim named as successor.

• Share buyback of up to JPY 100 billion to be initiated, reflecting strong cash flow.

Financial highlights

• Revenue for the first nine months exceeded JPY 3.5 trillion, up 9.8% year-over-year (4.5% at CER).

• Core operating profit reached JPY 1,006.3 billion, up 16.3% year-over-year (10.1% at CER); reported operating profit was JPY 417.5 billion, up 86.3%.

• Core EPS was 443 JPY; reported EPS was 134 JPY.

• Operating cash flow rose 90.8% to JPY 835 billion; adjusted free cash flow was JPY 568.3 billion, up 1,466% year-over-year.

• Gross margin was 66.0% for the period, down 1.5 percentage points year-over-year.

Outlook and guidance

• Full-year management guidance raised: revenue, core operating profit, and core margin all expected to grow.

• Updated forecast: JPY 4.59 trillion revenue, JPY 1.15 trillion core operating profit, JPY 507 core EPS, and 25.1% core OP margin.

• Free cash flow forecast increased to JPY 550–650 billion, reflecting improved performance and proceeds from a JV sale.

• Net profit forecast raised to JPY 118.0 billion (+73.5%).

• Management expects low-single-digit percentage increases in core revenue and core operating profit at CER, with core EPS flat to slightly declining.